Találati lista | Tudóstér

001-es BibID:	BIBFORM075566
Első szerző:	Nagy Gábor (laboratóriumi szakorvos, laboratóriumi hematológus és immunológus)
Cím:	Monitoring of drug level and anti-drug antibody production during vedolizumab therapy in patients with inflammatory bowel disease / G. Nagy, É. Török, K. Palatka, Z. Kébel, P. Antal-Szalmás
Dátum:	2018
Megjegyzések:	Integrin ?4?7 is expressed on gut-specific lymphocytes and plays a pivotal role in their migration to the intestine. Vedolizumab (VDZ, trade name Entyvio), a humanized monoclonal IgG1 antibody to the ?4?7 integrin blocks their adhesion to the gut vascular endothelium. In 2014 Entyvio was approved for patients with ulcerative colitis (UC) and Crohn's disease (CD) in Hungary. Our aim was to find and evaluate laboratory tests capable of measuring vedolizumab and anti-vedolizumab antibody (AVA) levels. After overviewing the available methods, LISA-TRACKER Duo Vedolizumab ELISA kit (ref: LTV 005, TheraDiag, Croissy-Beaubourg, France) was chosen. Seventeen samples of 15 patients (9 UC/6 CD) were analyzed. Mean VDZ levels were 18.2 ?g/mL and 7.4 ?g/mL in patients with UC and CD, respectively (p=0.242). Drug levels were significantly higher in patients on concomitant immune modulating therapy (16.9 ?g/mL vs 3.9 ?g/mL, p=0.033). There was no significant correlation between drug concentrations and CRP or disease activity scores. Anti-vedolizumab antibody was not detected in any of the patients (0/15) in accordance with the approximately 4% AVA positivity reported in vedolizumab immunogenicity studies (p=0.430). Five patients had drug levels under the measuring range of the test (<2 ?g/mL) suggesting the possibility of having low affinity anti-drug antibodies not detected by the bridging ELISA method used. In conclusion, LISA-TRACKER Duo Vedolizumab ELISA kit seems to be appropriate to monitor drug and anti-drug antibody levels in patients with inflammatory bowel disease. However, insensitivity of the ELISA methods for detecting low affinity anti-drug antibody may limit its use to determine immunogenicity of vedolizumab.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idézhető absztrakt
Megjelenés:	Clinical Chemistry and Laboratory Medicine. - 56 : 9 (2018), p. eA162. -
További szerzők:	Török Éva Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Kébel Z. Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: